Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

153 clusters · 502 sources · 94 days · First seen 3 months ago · Last updated about 11 hours ago

GLP‑1 market, safety, access, and new uses

Overview

Global demand for GLP‑1 anti‑obesity medicines keeps rising; a July 2026 U.S. Gallup poll found 11 % of adults using a GLP‑1 for weight loss. Eli Lilly’s Q1 sales of Mounjaro and Zepbound reached $12.9 bn, and the FDA approved the oral formulation Foundayo after the UK’s MHRA endorsed daily oral semaglutide for BMI ≥ 30. A temporary Medicare program reimburses GLP‑1s at $50 per month and a pilot proposes a modest co‑pay, yet out‑of‑pocket costs often exceed $1,000, fueling debate over affordability and weight stigma. Health‑journalism experts urged person‑first language (“people with obesity”) and highlighted broader health benefits. Trials show tirzepatide and the experimental combo CagriSema achieve average ~15 % weight loss; a BMJ meta‑analysis of 262 trials noted modest quality‑of‑life gains and that semaglutide injections lowered all‑cause mortality (19 %) and major cardiovascular events. Common side‑effects include “Ozempic feet,” a condition of thin foot pads and muscle that raises ulcer risk; podiatrists recommend monitoring foot health and adequate protein. Regulators in Brazil, the UK and Germany are tightening prescriptions and advancing next‑generation GLP‑1s. In South Africa, iDexis appeals a court interdict on compounded semaglutide, underscoring oversight of compounded products. Early longevity research showed an eight‑month semaglutide trial in people with HIV slowed biological‑age biomarkers. An emerging cosmetic market addresses volume loss from rapid GLP‑1‑induced fat reduction. In the United States, AlloClae—an injectable made from donated cadaveric fat—has treated over 2,000 patients since May 2025, costing about $2,250 per syringe to restore facial, breast and gluteal volume. The practice has sparked ethical debate and faces limited regulatory guidance. Starting July 1 2026, Medicare Part D added a flat $50 monthly copay for GLP‑1 weight‑loss drugs such as Wegovy, Zepbound and Foundayo, aiming to remove cost barriers for seniors.

Timeline

about 11 hours ago

[HEALTH] 2 sources
GLP‑1 receptor agonists explored for psoriasis, eczema and wound healing
A Pharmaceutics review highlights GLP‑1 agonists, known for diabetes treatment, as promising anti‑inflammatory agents for psoriasis, eczema and chronic wound healing, but notes limited clinical data.
about 12 hours ago

[HEALTH] 2 sources
GLP-1 drugs fuel celebrity weight‑loss debate and show promise in slowing biological aging
GLP‑1 drugs spark celebrity weight‑loss talk while new research shows semaglutide may slow biological aging in HIV patients.
about 20 hours ago

[HEALTH] 8 sources
GLP-1 weight‑loss drugs reshape U.S. health policy and consumer markets
U.S. Medicare now covers GLP‑1 weight‑loss drugs, pushing usage to 40 million adults; overdose cases spark safety worries, while retailers and Australian food firms adapt to shifting consumer habits.
2 days ago

[BUSINESS] 2 sources
South Africa's iDexis appeals court order on compounded weight‑loss drugs
South Africa's iDexis seeks to overturn a High Court order halting its compounded GLP‑1 weight‑loss drugs after regulators cited safety breaches; the firm says independent tests found no issues.
3 days ago

[HEALTH] 4 sources
Obesity drugs spark debate over access and stigma worldwide
US experts call for stigma‑free language and broader Medicare coverage of GLP‑1 obesity drugs, while South Africa debates their impact amid high obesity rates.
3 days ago

[HEALTH] 11 sources
US adopts cadaver‑fat injections to restore volume lost from GLP‑1 drugs
AlloClae, a US‑marketed injectable made from cadaver fat, is used to restore volume lost after GLP‑1 weight‑loss drugs, drawing rapid uptake, high costs and ethical debate.
5 days ago

[HEALTH] 8 sources
GLP‑1 Weight‑Loss Drugs Trigger “Ozempic Feet” Foot Changes
GLP‑1 weight‑loss drugs can cause loss of foot fat pads and muscle, leading to skin laxity, pain, shoe‑fit issues and higher ulcer risk, especially in diabetics.
5 days ago

[HEALTH] 2 sources
Polish health experts say obesity drugs need lifelong lifestyle support
Experts say obesity drugs like Ozempic work only with long‑term lifestyle changes; relapse rates remain high.
5 days ago

[HEALTH] 8 sources
German medical advances: improved GLP‑1 weight‑loss drugs and promising glioma vaccine
German firms test longer‑acting GLP‑1 weight‑loss drugs, while a new IDH1‑targeted glioma vaccine shows high survival rates in long‑term study.
6 days ago

[HEALTH] 2 sources
GLP‑1 and SGLT2 drugs studied for kidney health and crime reduction
Reviews find SGLT2 inhibitors protect kidneys in diabetic CKD, while GLP‑1 drugs aid metabolism; a Rutgers study links GLP‑1 use to reduced violent crime, though causality is unclear.
7 days ago

[HEALTH] 5 sources
South African regulators recall unlicensed Ozempic copies
South African regulators recall unlicensed Ozempic‑type drugs made by iDexis, warning pharmacists of fines and possible licence revocation after a court order blocks the company’s semaglutide products.
7 days ago

[HEALTH] 3 sources
Brazilian health experts shift focus from weight loss to muscle mass and body composition
Brazilian experts now prioritize muscle preservation and body composition over weight loss in obesity and ageing, promoting GLP‑1 therapies and strength training to improve health and independence.
8 days ago

[HEALTH] 12 sources
Obesity drugs cut weight but do not improve quality of life, study finds
A BMJ review of 262 trials finds obesity drugs like tirzepatide cut weight up to 15% but largely fail to improve quality of life, with limited heart benefits and higher side‑effects.
8 days ago

[HEALTH] 3 sources
Japan warns of off‑label weight‑loss use of diabetes drug Mounjaro
Japan warns that off‑label use of diabetes drug Mounjaro for weight loss may reduce contraceptive effectiveness and pose health risks, prompting health‑ ministry advisories.
8 days ago

[HEALTH] 5 sources
Ozempic prescription rules in Brazil amid surge in US poison‑center calls
Brazil mandates retained prescriptions for Ozempic under new 2025 rules, while U.S. poison‑center calls for semaglutide surged after its 2021 weight‑loss approval, driven by dosing errors.
9 days ago

[HEALTH] 3 sources
GLP‑1 weight‑loss drugs linked to joint, muscle and foot changes, prompting activity guidance
GLP‑1 weight‑loss drugs can reduce joint stress but may cause muscle loss, bone fragility and foot changes; doctors advise protein, resistance training and proper footwear, while UK guidelines stress strength‑b
9 days ago

[HEALTH] 13 sources
US Record Uptake of GLP-1 Weight‑Loss Drugs Spurs Market Surge
US adults on GLP‑1 weight‑loss drugs rose to 11 %, boosting sales and prompting new Medicare coverage, while side‑effects and global market growth spark health and policy debate.
10 days ago

[HEALTH] 2 sources
Ozempic and Mounjaro: How GLP‑1 and GIP drugs work for diabetes and weight loss
Ozempic and Mounjaro, GLP‑1‑based diabetes drugs, curb appetite and slow stomach emptying, causing notable weight loss but may cause nausea and weight regain after stopping.
10 days ago

[HEALTH] 9 sources
GLP‑1 weight‑loss drugs such as Ozempic transform markets, health outcomes and patient experiences worldwide
GLP‑1 drugs drive a booming market, boost job and partner prospects for U.S. women, cause facial changes, show no clear cognitive benefit, and face competition from a new oral pill with stronger effects but GI‑
10 days ago

[HEALTH] 7 sources
GLP-1 therapies face marketing, adherence and online prescription challenges
GLP‑1 drugs face supply, reimbursement and safety issues, show promise for osteoarthritis, see high early discontinuation, and are readily obtained online without clinician oversight.
11 days ago

[HEALTH] 2 sources
Weight-Loss Drugs Spur Record US Use and Boost Hiring for Unemployed Women
A Gallup poll shows a record 11% of Americans now use weight‑loss drugs as obesity falls, while a Harvard study links GLP‑1 use to a 27% hiring boost for unemployed women.
12 days ago

[HEALTH] 2 sources
GLP‑1 drugs show cardiovascular benefits and potential aggression link, studies reveal
Semaglutide cuts cardiovascular events by 20 % independent of weight loss, while some reports link GLP‑1 drugs to impulsivity and aggression.
14 days ago

[HEALTH] 3 sources
Study finds GLP-1 drugs boost job prospects for unemployed women; Vermont health network ends weight‑loss coverage
A Harvard study links GLP‑1 weight‑loss drugs to a 27% rise in employment for unemployed women, while Vermont’s UVM Health will drop coverage for these drugs to cut costs.
15 days ago

[HEALTH] 2 sources
GLP-1 weight‑loss therapy warned of muscle loss; experts recommend protein and resistance training
Experts warn that GLP‑1 weight‑loss drugs can cause muscle loss and advise adequate protein, resistance training, and vitamin D/omega‑3 support, all under medical supervision.
16 days ago

[HEALTH] 2 sources
GLP-1 Weight‑Loss Drugs May Extend Lifespan, Researchers Say
Early research suggests GLP‑1 weight‑loss drugs like semaglutide may slow biological aging, but evidence is insufficient to confirm lifespan extension in healthy people, and safety concerns remain.
16 days ago

[HEALTH] 13 sources
Medicare Launches $50 GLP‑1 Weight‑Loss Drug Pilot for Seniors
Medicare’s $50 GLP‑1 Bridge pilot, starting July 1 2026, offers Wegovy, Zepbound KwikPen and Foundayo to eligible seniors with specific BMI thresholds, covering up to 3.8 million beneficiaries through 2027.
16 days ago

[HEALTH] 4 sources
GLP‑1 receptor agonists cut deaths in diabetic PAD patients yet raise psychiatric risk
GLP‑1 receptor agonists lowered death, amputation and hospitalization rates in diabetics with PAD, while a US claims study found a 48% higher risk of psychiatric events, including depression and anxiety, among
16 days ago

[HEALTH] 10 sources
Brazil's GLP-1 drug market expands as prices drop and parallel sales surge
Brazil’s GLP‑1 market is booming, with half the doses sold informally, Eurofarma cutting prices to as low as R$295, studies showing health benefits, and generic options expected to boost patient access from 28%
18 days ago

[HEALTH] 7 sources
Netherlands sees double poisonings from injectable weight‑loss drugs
Dutch poison centre says reports of injectable weight‑loss drug poisonings doubled to 149 in 2025, with many cases involving unprescribed semaglutide, liraglutide, tirzepatide and experimental retatrutide.
18 days ago

[HEALTH] 2 sources
Diabetes treatments shown to lower heart complications in hospital and genetic studies
Spanish hospital research shows combined insulin and SGLT2/GLP‑1 therapy halves hypoglycaemia risk, while a U.S. genetic study finds dapagliflozin cuts heart‑failure admissions up to 80 % in high‑risk diabetics
18 days ago

[HEALTH] 3 sources
GLP‑1 drugs ease food‑noise while experts list natural appetite‑suppressing foods
GLP‑1 drugs may lessen intrusive “food‑noise” thoughts, while experts recommend foods like eggs, legumes, dark chocolate and fish to naturally curb appetite.
18 days ago

[HEALTH] 2 sources
GLP-1 obesity drugs receive US guideline endorsement as trial shows muscle‑preserving option
US guidelines now prioritize semaglutide and tirzepatide for obesity, and an early trial shows adding an anti‑myostatin antibody to tirzepatide can halve muscle loss while preserving weight‑loss benefits.
18 days ago

[HEALTH] 6 sources
GLP‑1 weight‑loss drugs offer heart benefits but need lasting lifestyle plan
GLP‑1 weight‑loss drugs like Ozempic cut heart risk and may affect behaviour and ageing, but doctors stress a lasting lifestyle plan to keep weight off after treatment.
20 days ago

[HEALTH] 4 sources
GLP-1 Diabetes Drugs Linked to Increased Smell and Taste Disturbances, Study Finds
GLP‑1 diabetes drugs raise the risk of smell (81 %) and taste (52 %) disturbances, while a dexamethasone pre‑dose cuts early morphine‑induced nausea in cancer patients.
20 days ago

[HEALTH] 2 sources
AstraZeneca's oral diabetes drug elecoglipron cuts blood sugar and weight in trial
AstraZeneca’s oral diabetes drug elecoglipron lowered HbA1c in 90% of trial participants and led to significant weight loss, showing promise as an injectable‑free treatment.
20 days ago

[HEALTH] 6 sources
GLP‑1 drugs linked to higher risk of smell and taste disorders
A study of 438,474 patients shows GLP‑1 drugs like Ozempic raise the risk of smell and taste loss by 38 %, a risk that lasts up to two years but remains low in absolute terms.
20 days ago

[HEALTH] 2 sources
Weight‑loss injections cause severe side effects as Taiwan promotes needle‑knife therapy
A Japanese woman experienced severe side effects from weight‑loss injections, while Taiwanese doctors tout a minimally invasive needle‑knife method for obesity, highlighting the need for professional oversight.
21 days ago

[HEALTH] 10 sources
GLP-1 diabetes drugs linked to altered smell, taste and possible fertility benefits
GLP‑1 diabetes drugs raise risk of smell and taste disorders by 38 % while a UK study shows they may improve male fertility markers, prompting calls for monitoring.
21 days ago

[HEALTH] 6 sources
GLP-1 weight‑loss drugs raise safety and misuse concerns
Experts discuss GLP‑1 side effects on Reddit, while a study shows high misuse among eating‑disorder patients, prompting safety concerns.
21 days ago

[HEALTH] 6 sources
Turkish dietitian Hale Aslantaş says bread can stay in balanced weight‑loss diets
Dietitian Hale Aslantaş urges balanced meals, modest bread intake, regular activity and sleep for healthy weight loss, warning against extreme diets and noting GLP‑1 drugs aren’t a sole fix.
21 days ago

[HEALTH] 3 sources
Brazil's obesity drug surge sparks metabolic health warnings
Brazilian doctors warn that weight‑loss drugs like Ozempic shrink the scale but often leave metabolic problems unresolved, with up to 30% of patients not responding due to misuse, genetics or insulin resistance
21 days ago

[HEALTH] 2 sources
Brazil GLP‑1 drug market grows modestly, informal sector supplies over half of doses
Brazil’s pharma market grew 5.8% in May, driven mainly by GLP‑1 pens, while a study finds over half of GLP‑1 doses are sold through the informal sector, with usage up 239% in Q1 2026.
22 days ago

[HEALTH] 3 sources
Uganda and South Africa tighten drug licensing and GLP‑1 medicine regulations
Uganda’s health ministry told the AHPC to stop licensing drug shops, delegating authority to the NDA, while South Africa’s SAHPRA and SAPC seized illegal GLP‑1 medicines and ordered a recall after finding non‑c
23 days ago

[HEALTH] 2 sources
GLP-1 agonists studied for skin disorders and reduced breast cancer incidence
GLP‑1 agonists may aid chronic inflammatory skin diseases and are linked to about a 30% lower breast cancer risk in women, though more research is needed.
23 days ago

[HEALTH] 4 sources
German survey shows high awareness but caution on weight‑loss injections
A German survey of 409 people shows 79 % know weight‑loss drugs like Wegovy, but most fear side effects and feel poorly informed.
24 days ago

[HEALTH] 2 sources
Novo Nordisk Secures Interim Injunction Against iDexis Over Semaglutide Products
South Africa's Gauteng High Court issued an interim order blocking iDexis from making and selling unregistered semaglutide weight‑loss drugs after Novo Nordisk sued, citing safety concerns and a wider fight to止
24 days ago

[HEALTH] 7 sources
Brazil's GLP‑1 weight‑loss drugs drive health research, sales surge and informal market
GLP‑1 weight‑loss drugs in Brazil are linked to reduced cancer progression risk, a 153% sales jump, more body‑contouring surgeries, and an informal market possibly supplying over half the doses.
24 days ago

[HEALTH] 4 sources
Ozempic and Other GLP‑1 Drugs Linked to Rapid Facial Changes and Skin Concerns
GLP‑1 drugs like Ozempic cause rapid weight loss that can lead to facial volume loss (“Ozempic face”), skin sagging, and broader appetite‑suppression effects, prompting medical advice on gradual loss and cautio
25 days ago

[HEALTH] 6 sources
Weight‑loss injection drugs raise concerns over muscle loss and skin laxity
Injectable obesity drugs like semaglutide are booming, but experts warn they can cause muscle loss, skin laxity and rebound weight without proper metabolic assessment and individualized care.
26 days ago

[HEALTH] 2 sources
GLP‑1 weight‑loss drugs linked to lower violent crime rates in US study
Rutgers study of 821 US adults shows GLP‑1 weight‑loss drugs are associated with reduced impulsive violent crime, highlighting possible behavioral effects of the medication.
26 days ago

[HEALTH] 5 sources
GLP-1 drugs plus lifestyle counseling achieve top weight loss in youth
Research shows GLP‑1 drugs like semaglutide cut BMI most effectively in youths when paired with intensive lifestyle counseling, but many patients reduce physical activity, underscoring the need for combined, on
26 days ago

[HEALTH] 3 sources
Tirzepatide outperforms semaglutide in weight‑loss efficacy, meta‑analysis shows
A meta‑analysis of 15 trials with over 14,000 non‑diabetic patients finds tirzepatide leads to >20% weight loss, surpassing semaglutide’s ~14% and liraglutide’s ~8%.
27 days ago

[HEALTH] 2 sources
New BRP peptide shows promise as safe obesity therapy
Stanford scientists discovered a 12‑amino‑acid peptide (BRP) that curbs appetite and weight in animal tests without typical GLP‑1 drug side effects, while a U.S. study linked GLP‑1 medications to reduced risk‑y
27 days ago

[HEALTH] 2 sources
Czech doctors recommend consistent sleep schedules and cautious intermittent fasting
Czech health experts advise regular sleep times for heart, metabolic and mental benefits, and caution that intermittent fasting helps weight loss but isn’t suitable for everyone.
27 days ago

[HEALTH] 8 sources
GLP-1 Drugs Prompt Surge in Cosmetic Procedures, Coverage Gaps and Climate Debate
GLP-1 drugs are spurring more cosmetic surgeries for weight‑loss side effects, exposing Medicare coverage gaps, prompting lawsuits, and influencing U.S. food‑system emissions and obesity treatment.
27 days ago

[HEALTH] 2 sources
Czech nutritionists warn women against fasting and highlight obesity drug guidance
Czech nutritionists advise women against restrictive fasting, stressing balanced diet and muscle health, while doctors discuss obesity drugs that can aid 10‑20% weight loss but require lifestyle changes.
27 days ago

[HEALTH] 3 sources
GLP‑1 Weight‑Loss Drugs and Diet Trends Raise Health Concerns
GLP‑1 drugs are being used off‑label for extreme thinness, raising hormonal and fertility risks, while low‑GI food guidance helps diabetics manage blood sugar.
27 days ago

[HEALTH] 2 sources
GLP-1 weight‑loss drugs linked to higher testosterone and improved sperm quality in obese men
Studies presented at ENDO 2026 and reported by CNN found GLP‑1 weight‑loss drugs may raise testosterone and improve sperm count and quality in obese men, though evidence remains limited.
27 days ago

[HEALTH] 6 sources
Ozempic and other GLP‑1 drugs spark wide‑range effects from fashion returns to health outcomes
Ozempic and similar GLP‑1 drugs are leading to higher fashion‑retail returns, better weight loss than surgery, reduced impulsive violence, modest early weight loss, cosmetic ear changes, and a 15 % drop in bone
28 days ago

[HEALTH] 2 sources
GLP-1 weight‑loss drugs cut obesity‑related cancer risk by up to 58%
Study of 229,000 obese adults shows GLP‑1 weight‑loss drugs lower overall obesity‑related cancer risk by 41%, with up to 58% drop for endometrial cancer.
28 days ago

[HEALTH] 8 sources
GLP-1 Drugs Show Cancer Risk Reduction but Raise Hypotension Concerns Amid Industry Boom
GLP-1 drugs cut obesity‑related cancer risk but increase fainting and dizziness risk, especially in older patients, while becoming a blockbuster pharma platform.
28 days ago

[HEALTH] 4 sources
GLP‑1 weight‑loss drugs weaken link between impulsivity and violence
Rutgers researchers found that U.S. users of GLP‑1 weight‑loss drugs show a 62 % weaker link between impulsivity and violence and a 52 % weaker link with alcohol‑related aggression.
29 days ago

[HEALTH] 3 sources
Brazil's GLP‑1 weight‑loss pens spark surge in lab testing and post‑weight‑loss health debate
Brazil’s GLP‑1 weight‑loss pens have spurred a surge in lab monitoring and raised concerns about post‑weight‑loss health, prompting tighter regulations and calls for broader patient support.
30 days ago

[HEALTH] 3 sources
US FDA issues 25 warning letters to telehealth firms over false weight‑loss drug claims
The US FDA sent 25 warning letters to telehealth companies for false claims about compounded GLP‑1 weight‑loss drugs, citing safety concerns and a broader crackdown on unapproved compounds.
about 1 month ago

[HEALTH] 5 sources
GLP-1 drugs reshape obesity treatment and may lower addiction risk
GLP‑1 weight‑loss drugs are expanding use, prompting concerns they may supplant bariatric surgery in Brazil, where surgery numbers fell 18% in 2024, while a U.S. veteran study links GLP‑1 use to a 14% drop in新‑
about 1 month ago

[HEALTH] 2 sources
GLP‑1 drugs drive major shift in fitness industry and spark calls for integrated exercise programs
Consultants foresee GLP‑1 drugs reshaping gyms and consumer habits, while a multinational study shows adding structured exercise to GLP‑1 therapy yields billions in health‑economic value and calls for policy‑dr
about 1 month ago

[HEALTH] 2 sources
Bariatric surgery and Mounjaro highlighted as effective weight‑loss treatments
Bariatric surgery and the drug Mounjaro are presented as hormonal approaches that improve metabolic health and enable sustainable weight loss, with examples from Australia and the UAE.
about 1 month ago

[HEALTH] 5 sources
GLP‑1 therapy and satiety‑rich foods promoted for weight‑loss
Experts highlight satiety‑rich foods and GLP‑1 therapy as effective weight‑loss methods, noting benefits and common gastrointestinal side‑effects.
about 1 month ago

[HEALTH] 2 sources
GLP‑1 obesity drugs associated with lower daily activity in patients
A study of 753 US adults on GLP‑1 obesity drugs found daily steps and vigorous activity drop after treatment, while a German TV program will address the drugs' effects, risks and diet guidance.
about 1 month ago

[HEALTH] 2 sources
Czech health minister Vojtěch stresses prevention over drugs for child obesity
Czech health minister Adam Vojtěch says weight‑loss drugs should be limited to severe child obesity cases and combined with lifestyle changes, supporting preventive programmes like Be Fit 24.
about 1 month ago

[HEALTH] 2 sources
Semaglutide Study Shows Slower Biological Aging in People with HIV
A UC San Diego trial found weekly semaglutide injections slowed biological aging markers by about 9% in 108 HIV‑positive adults, though it is not an anti‑aging drug.
about 1 month ago

[HEALTH] 5 sources
GLP-1 drugs linked to reduced exercise and about 30% lower breast cancer risk
GLP-1 drugs like Ozempic are tied to less physical activity in obese patients and about a 30 % lower breast‑cancer risk in women, prompting calls for exercise support and more research.
about 1 month ago

[HEALTH] 5 sources
GLP-1 Weight‑Loss Drugs Linked to Lower Physical Activity in Obesity Patients
Study presented at ENDO 2026 shows GLP‑1 obesity drugs cut daily steps and vigorous activity, while another analysis reveals high early discontinuation rates that improve with specialist care and newer agents.
about 1 month ago

[HEALTH] 2 sources
GLP-1 drugs linked to higher diabetic foot complications and increased hypotension risk
GLP‑1 receptor agonists show lower diabetic foot complication rates than SGLT2 inhibitors but increase hypotensive events among hypertensive patients, especially older adults.
about 1 month ago

[HEALTH] 2 sources
Czech health officials warn of muscle loss from weight‑loss injection drugs
Czech doctors say prescription weight‑loss injections can cut appetite but risk muscle loss; patients need diet, exercise and monitoring, and the therapy costs about 70 k CZK.
about 1 month ago

[HEALTH] 4 sources
GLP-1 drugs associated with health gains and lower addiction rates in the United States
US research links GLP‑1 weight‑loss drugs to reduced substance‑use disorder rates and underscores tennis as a high‑impact exercise for lasting health.
about 1 month ago

[HEALTH] 7 sources
UK approves first oral GLP‑1 obesity pill as trials show diabetes benefits and cancer‑metastasis reduction
Oral GLP‑1 pills show strong diabetes control, weight loss and may cut cancer metastasis; UK approves Novo Nordisk's tablet, while new non‑GLP‑1 oral compounds also emerge.
about 1 month ago

[HEALTH] 3 sources
GLP‑1 weight‑loss drugs spur rise in cosmetic surgery demand in Spain
GLP‑1 drugs like Ozempic and Mounjaro are causing rapid weight loss, leading to increased skin laxity and a surge in cosmetic surgery demand in Spain, while doctors stress proper nutrition and monitoring.
about 1 month ago

[HEALTH] 4 sources
GLP‑1 weight‑loss drugs linked to lower cancer rates in early studies
Early ASCO data link GLP‑1 weight‑loss drugs to lower rates of several cancers, but findings remain observational and unproven.
about 1 month ago

[HEALTH] 4 sources
GLP‑1 weight‑loss drugs drive consumer changes in Brazil and a muscle‑preserving trial in the US
Brazil's GLP‑1 drug use reshapes consumer habits toward healthier foods and lifestyle spending, while a US trial shows apitegromab may protect muscle during tirzepatide weight loss, though with limited clinical
about 1 month ago

[HEALTH] 2 sources
Brazil's weight‑loss injection pens reshape food market and health research
Brazil's weight‑loss injection pens are driving healthier food choices and prompting market shifts, while early studies suggest they may also cut obesity‑related cancer risk.
about 1 month ago

[HEALTH] 2 sources
AstraZeneca's oral GLP‑1 drug elecoglipron cuts blood sugar and body weight in phase‑2 trials
AstraZeneca’s oral GLP‑1 pill elecoglipron cut HbA1c up to 1.9 % and body weight up to ~12 % in phase‑2 trials, prompting phase‑3 development.
about 1 month ago

[HEALTH] 6 sources
GLP-1 drugs linked to slowed aging and reduced muscle loss
Semaglutide may slow biological aging in HIV patients, while apitegromab reduces muscle loss by over half when combined with tirzepatide.
about 1 month ago

[HEALTH] 3 sources
Ozempic and other GLP‑1 drugs reshape weight‑loss culture and medical practice
GLP‑1 drugs like Ozempic, Wegovy and Mounjaro, originally for diabetes, are now used for weight loss, prompting medical guidance on lifelong use and sparking debate over cultural ideals of thinness.
about 1 month ago

[HEALTH] 7 sources
GLP-1 medications widen applications while safety and regulatory concerns emerge
GLP‑1 drugs expand beyond diabetes to obesity, heart health and potential cancer risk reduction, while unauthorized knockoffs raise safety concerns, and patients report mood changes, muscle loss and weight‑loss
about 1 month ago

[HEALTH] 2 sources
GLP-1 weight‑loss drugs tied to lower breast cancer risk and reported ADHD improvements
U.S. studies link GLP-1 weight‑loss drugs to a 30‑35 % reduction in breast cancer risk and report anecdotal ADHD symptom improvements among users.
about 1 month ago

[BUSINESS] 2 sources
GLP‑1 weight‑loss injections linked to mental health effects and potential fuel savings for Brazil's Azul
GLP‑1 weight‑loss injections cause mood and anxiety issues, while Azul airline expects up to R$3 million monthly fuel savings as passengers shed weight.
about 1 month ago

[HEALTH] 3 sources
GLP‑1 weight‑loss drugs spur rise in cosmetic procedures for ears and buttocks
GLP‑1 weight‑loss drugs are causing ear and buttock shape changes, leading to more cosmetic surgeries; muscle loss is a concern, with exercise and a new myostatin‑blocking drug under study.
about 1 month ago

[HEALTH] 2 sources
GLP-1 medications linked to lower breast cancer risk and new oral pill cuts diabetes and weight
Observational data link GLP‑1 drugs to reduced breast cancer risk, while AstraZeneca’s new oral GLP‑1 pill showed strong glucose and weight loss benefits in a phase‑2B trial.
about 1 month ago

[HEALTH] 3 sources
AstraZeneca's Elecoglipron achieves 10% weight loss in phase‑2 trial
AstraZeneca's oral GLP‑1 drug elecoglipron cut weight by ~10% in a phase‑2 trial of 310 obese adults, showing safety comparable to injectables and prompting plans for phase‑3 studies.
about 1 month ago

[HEALTH] 2 sources
AstraZeneca's oral obesity drug elecoglipron cuts weight up to 11.8% in trial
AstraZeneca's oral GLP‑1 drug elecoglipron reduced weight by up to 11.8% in a phase‑II trial of 310 obese adults, with common GI side effects, aiming to compete with Novo Nordisk and Eli Lilly products.
about 1 month ago

[HEALTH] 4 sources
GLP-1 drugs Ozempic and Wegovy linked to 30% lower breast cancer risk in large US study
US study of 111,646 women links GLP‑1 drugs Ozempic/Wegovy to roughly 30 % lower breast‑cancer risk, though causality remains unproven.
about 1 month ago

[HEALTH] 6 sources
GLP‑1 weight‑loss drugs cut cancer risk; apitegromab adds muscle‑preserving benefit
GLP‑1 drugs lower obesity‑cancer risk; apitegromab cuts muscle loss by up to 55% in tirzepatide users.
about 1 month ago

[HEALTH] 2 sources
GLP‑1 weight‑loss drugs approved in Scotland and shown to cut heart risk in autoimmune patients
Research shows GLP‑1 drugs cut heart‑related risks in obese autoimmune patients, and Scotland approves Wegovy for overweight adults with cardiovascular disease.
about 1 month ago

[HEALTH] 2 sources
GLP‑1 Drugs Cut Substance Abuse Risk; New Oral Pill Targets Muscle Metabolism for Diabetes
A U.S. study finds GLP‑1 drugs lower odds of alcohol, opioid, nicotine and cocaine disorders, while researchers in Sweden report a new oral pill that boosts muscle metabolism to treat type‑2 diabetes and obese.
about 1 month ago

[HEALTH] 4 sources
GLP‑1 drugs linked to body changes, muscle loss concerns and possible lower breast‑cancer risk
GLP‑1 drugs cause rapid weight loss with side effects like facial and vulvar changes, prompting muscle‑preserving exercise advice; a study of 111,000 women suggests they may also lower breast‑cancer risk, but a
about 1 month ago

[HEALTH] 4 sources
Diabetology Limited reports first human data on oral GLP‑1 drug Oraglutide
Diabetology Limited presented first human data on oral GLP‑1 drug Oraglutide at the ADA conference, showing 14 % glucose reduction, increased insulin, no side‑effects and potency over six times that of Rybelsus
about 1 month ago

[HEALTH] 2 sources
German Court Blocks Private Insurance Reimbursement for Weight‑Loss Drug Mounjaro
A German court ruled that private health insurers must not cover Mounjaro weight‑loss injections without proven medical necessity, rejecting a claim by a 53‑year‑old patient with obesity and diabetes.
about 1 month ago

[HEALTH] 5 sources
Oral GLP‑1 therapies improve blood sugar and weight in type‑2 diabetes trials
Oral GLP‑1 drugs orforglipron and elecoglipron cut blood‑sugar and weight in type‑2 diabetes patients on basal insulin, showing promise as needle‑free therapies.
about 1 month ago

[HEALTH] 7 sources
GLP‑1 weight‑loss drugs linked to lower breast and obesity‑related cancer risk
U.S. studies find GLP‑1 weight‑loss drugs cut breast cancer odds by ~30% and overall obesity‑related cancer risk by 41%, though benefits vary by race.

Sources

10perc.hu · 24matins.es · abc17news.com · abc7chicago.com · abradilan.com.br · acceleratedwebsystems.com · acsh.org · activistpost.com · actualidad.rt.com · aeiou.pt · africa.businessinsider.com · ahdb.org.uk · aijourn.com · akeza.net · albrandswaardsdagblad.nl · aldia.cat · alfavita.gr · allurantmedical.com · am730.ca · americanbazaaronline.com · amp.krone.at · ar.vogue.me · archynewsy.com · archyworldys.com · ariananews.af · ascendwrestling.com · athensmagazine.gr · athina984.gr · athletechnews.com · aufeminin.com · bariatricsurgeries.com · beauty-heroes.com · beautypost.jp · benningtonbanner.com · beobachtertv.ch · bigeasymagazine.com · bikeregister.com · bilder4.n-tv.de · bizcommunity.com · blackdoctor.org · blitzquotidiano.it · bmmagazine.co.uk · bolnews.com · bonsfluidos.com.br · brainflow.co · brasilemfolhas.com.br · braunschweiger-zeitung.de · BriefingWire.com